Flexible Subscriptions to Match your Budget and Timeline See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Colorcon
Merck
Medtronic
Mallinckrodt
McKesson

Last Updated: January 24, 2022

DrugPatentWatch Database Preview

Investigational Drug Information for Staurosporine


Email this page to a colleague

« Back to Dashboard

What is the development status for investigational drug Staurosporine?

Staurosporine is an investigational drug.

There have been 31 clinical trials for Staurosporine. The most recent clinical trial was a Phase 2 trial, which was initiated on December 22nd 2017.

The most common disease conditions in clinical trials are Leukemia, Leukemia, Myeloid, Acute, and Leukemia, Myeloid. The leading clinical trial sponsors are National Cancer Institute (NCI), University Health Network, Toronto, and Sidney Kimmel Comprehensive Cancer Center.

There are six hundred and twenty-five US patents protecting this investigational drug and fifteen international patents.

Recent Clinical Trials for Staurosporine
TitleSponsorPhase
Testing the Combination of Standard Induction Therapy With Gemtuzumab Ozogamicin and Midostaurin as a Novel Approach to Treating Patients With Newly Diagnosed FLT-3 Mutated Acute Myeloid LeukemiaFred Hutchinson Cancer Research CenterPhase 1
Testing the Combination of Standard Induction Therapy With Gemtuzumab Ozogamicin and Midostaurin as a Novel Approach to Treating Patients With Newly Diagnosed FLT-3 Mutated Acute Myeloid LeukemiaOregon Health and Science UniversityPhase 1
Testing the Combination of Standard Induction Therapy With Gemtuzumab Ozogamicin and Midostaurin as a Novel Approach to Treating Patients With Newly Diagnosed FLT-3 Mutated Acute Myeloid LeukemiaPfizerPhase 1

See all Staurosporine clinical trials

Clinical Trial Summary for Staurosporine

Top disease conditions for Staurosporine
Top clinical trial sponsors for Staurosporine

See all Staurosporine clinical trials

US Patents for Staurosporine

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Staurosporine ⤷  Sign up for a Free Trial Heat shock protein 70 (hsp-70) receptor ligands Duke University (Durham, NC) ⤷  Sign up for a Free Trial
Staurosporine ⤷  Sign up for a Free Trial Pyrazol-3-ones that activate pro-apoptotic BAX Dana-Farber Cancer Institute, Inc. (Boston, MA) ⤷  Sign up for a Free Trial
Staurosporine ⤷  Sign up for a Free Trial Monomethylvaline compounds having phenylalanine side-chain modification at the C-terminus Seattle Genetics, Inc. (Bothell, WA) ⤷  Sign up for a Free Trial
Staurosporine ⤷  Sign up for a Free Trial Substituted indole Mcl-1 inhibitors Vanderbilt University (Nashville, TN) ⤷  Sign up for a Free Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for Staurosporine

Drugname Country Document Number Estimated Expiration Related US Patent
Staurosporine World Intellectual Property Organization (WIPO) WO2015148714 2034-03-25 ⤷  Sign up for a Free Trial
Staurosporine Australia AU2012322660 2031-10-11 ⤷  Sign up for a Free Trial
Staurosporine Australia AU2017228527 2031-10-11 ⤷  Sign up for a Free Trial
Staurosporine Canada CA2851788 2031-10-11 ⤷  Sign up for a Free Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Colorcon
Merck
Medtronic
Mallinckrodt
McKesson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.